Literature DB >> 17237221

Going from genes to proteins in myelodysplastic syndromes.

Arnold Ganser1, Michael A Morgan, Eva M Weissinger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17237221      PMCID： PMC1783135          DOI： 10.1073/pnas.0610831104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  19 in total

1.  Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction.

Authors:  A Miyazato; S Ueno; K Ohmine; M Ueda; K Yoshida; Y Yamashita; T Kaneko; M Mori; K Kirito; M Toshima; Y Nakamura; K Saito; Y Kano; S Furusawa; K Ozawa; H Mano
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

2.  Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease.

Authors:  Manuel Aivado; Dimitrios Spentzos; Ulrich Germing; Gil Alterovitz; Xiao-Ying Meng; Franck Grall; Aristoteles A N Giagounidis; Giannoula Klement; Ulrich Steidl; Hasan H Otu; Akos Czibere; Wolf C Prall; Christof Iking-Konert; Michelle Shayne; Marco F Ramoni; Norbert Gattermann; Rainer Haas; Constantine S Mitsiades; Eric T Fung; Towia A Libermann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-12       Impact factor: 11.205

3.  Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow.

Authors:  Wolf-K Hofmann; Sven de Vos; Martina Komor; Dieter Hoelzer; William Wachsman; H Phillip Koeffler
Journal:  Blood       Date:  2002-11-15       Impact factor: 22.113

4.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

5.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

6.  Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation.

Authors:  Thorsten Kaiser; Haytham Kamal; Andreas Rank; Hans-Jochem Kolb; Ernst Holler; Arnold Ganser; Bernd Hertenstein; Harald Mischak; Eva Maria Weissinger
Journal:  Blood       Date:  2004-03-30       Impact factor: 22.113

7.  Measurement of serum cytokine levels in patients with myelodysplastic syndromes.

Authors:  G E Verhoef; P De Schouwer; J L Ceuppens; J Van Damme; W Goossens; M A Boogaerts
Journal:  Leukemia       Date:  1992-12       Impact factor: 11.528

8.  Platelet-derived chemokines CXC chemokine ligand (CXCL)7, connective tissue-activating peptide III, and CXCL4 differentially affect and cross-regulate neutrophil adhesion and transendothelial migration.

Authors:  Birgit I Schenk; Frank Petersen; Hans-Dieter Flad; Ernst Brandt
Journal:  J Immunol       Date:  2002-09-01       Impact factor: 5.422

9.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis.

Authors:  Katherine R Kozak; Malaika W Amneus; Suzanne M Pusey; Feng Su; Mui N Luong; Sam A Luong; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-01       Impact factor: 11.205

10.  Application of capillary electrophoresis/ electrospray ionization-mass spectrometry to subcellular proteomics of Escherichia coli ribosomal proteins.

Authors:  Mehdi Moini; Hsiaoling Huang
Journal:  Electrophoresis       Date:  2004-07       Impact factor: 3.595
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.